Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

Not Applicable

• Conditions: Type2 Diabetes
• Interventions: Drug: Rifaximin 200 MG

• Registration Number: NCT03758144
• Lead Sponsor: Zagazig University

Brief Summary

Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

Detailed Description

Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin

Study Timeline

• Status Verified: 2018-11
• Study Start: 2018-11-01
• Study First Submitted: 2018-11-16
• Study First Submitted QC: 2018-11-28
• Last Update Submitted: 2018-11-28
• Study First Posted: 2018-11-29
• Last Update Posted: 2018-11-29
• Primary Completion: 2019-06
• Study Completion: 2019-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• diabetes with gut dysbiosis

Exclusion Criteria

• recent antibiotic use
• pregnancy
• diabetogenic drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
study	Rifaximin 200 MG	-

Primary Outcome Measures

Name	Time	Method
change in glycemic control	3 months	Fasting blood sugar, post-prandial blood sugar (mg/dl)

Secondary Outcome Measures

Name	Time	Method
Gastrointestinal symptom questionnaire	1 month	symptomatic improvement in Dyspepsia, distension, abdominal pain

Trial Locations

Locations (1)

Zagazig University; 🇪🇬 Zagazig, Sharkia, Egypt